



Physis International LLC
 Email: physis-mail@physisinternational.com
 Phone: (866)-611-1702
<https://physisinternational.com>

IN OHIO:
 6154 Tetlin Field Drive
 New Albany, OH 43054-8612

ABOUT PHYSIS INTL & COMPETENCY: Physis has developed unique IP-protected

immune-modulating agents that have outstanding clinical and economic return potential for multiple disease realms, including oncology, rheumatology (RA), cardiovascular disease (CVD), and treatment of infectious disease (ID). Physis stands ready to develop and when feasible, consider partnerships for their market-disruptive, and clinically adapted agents derived from prior FDA approved modules. This places Physis in a unique drug development position where costs, regulatory requirements, and time-to-market are markedly obviated. The clinical experience with our drug platform allows for a powerful risk-mitigated development approach. Physis looks forward to collaborations, partners, and synergies that provide expedited development for its agents with the patient- and outcomes-centered efforts leading to high ROIs.

PROGRAM	PRECLIN.	PHASE 1	PHASE 2	PHASE 3	505(B)2	OTC	
PHY-001							
Target cell phenotype-shifting for solid tumors, RA, CVD							
PHY-002							
Target cell phenotype-shifting for alt disease states							
PHY-003							
Targeting anergic or other immune cells for mitochondrial disruption & apoptosis induction							
PHY-004							
Gene therapy, allowing narrow creation of the CD206 receptor in target tissue as a target for PHY-003							
PHY-005							
Targeting inflammatory bowel disease- down regulating inflammation of GI immune cells							
PHY-006							
Down regulation of macrophages or their elimination in diabetic retinopathy							
PHY-007							
Pain relief drug delivered topically/focally (anti-inflammatory cream, gel, spray, patch, roll-on balm).							
PHY-008							
Down regulation of macrophages or their elimination in wet MD							
PHY-009							
Vaccine delivery system with targeted antigen delivery (includes protein, RNA and DNA payloads)							
PHY-010							
Library of new molecular entities for immuno-therapy in immune therapy platform							

DIFFERENTIATION: Physis' approach to rapid drug-to-clinic-to-patient outcome is the repurposing of existing FDA-approved drugs & formulations. Additionally, revelations resulting from this process produce new and even more potent agents for fighting cancer and chronic debilitating diseases. Such approaches provide exceptional opportunities not realized in usual drug development pathways. This approach lowers costs & speeds life-saving therapies.

PERFORMANCE: Physis is led by three highly experienced personnel with more than 95 years of successful drug development and FDA approvals. Their successful experience is realized in infectious disease, diabetes, cardiology AIDS, cancer, and inflammatory disease, with additional device experience in cancer diagnostics. Their successes have had a positive impact on the lives of millions of patients worldwide.

CERTIFICATIONS: CITI CERTIFIED, CNS, FACN, FACEM, CRA, FWA APPROVED, etc.

NAICS, PSC, & SIC CODES: 325412, 541714, 541715, 541990 (NAICS); 6505, 6508, 6509 (PSC); 8731, 2833, 2835 (SIC).

POC: 866-611-1702 or 614-804-0384; physis-mail@physisinternational.com

